Immune Checkpoint Inhibitors Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Immune Checkpoint Inhibitors Market to 2027 - Global Analysis and Forecasts by Type (CTLA-4 Inhibitor, PD-1 Inhibitor and PD-L1 Inhibitor); Application (Lung Cancer and Bladder Cancer)

Report Code: TIPRE00003749 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Immune Checkpoint Inhibitors are types of drugs used in immunotherapy which targets the cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by immune system.

MARKET DYNAMICS
The Immune Checkpoint Inhibitors market is anticipated to grow in the forecast period owing to driving factors such as large population base, growth in awareness about advanced immune therapy, rise in incidence of cancer and improvement of healthcare infrastructure especially in countries like India and China. Nevertheless, the high cost in the research and development of this market can hinder the market growth during the forecast period.

MARKET SCOPE
The "Global Immune Checkpoint Inhibitors Market Analysis to 2027" is a specialized and in-depth study of the Biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of Immune Checkpoint Inhibitors market with detailed market segmentation by Dosage, Route of Administration, Application and geography. The global Immune Checkpoint Inhibitors market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Immune Checkpoint Inhibitors market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Immune Checkpoint Inhibitors market is segmented on the basis of Type and Application. On the basis of Type the market is segmented as CTLA-4 Inhibitor, PD-1 Inhibitor and PD-L1 Inhibitor. On the basis of Application, the market is segmented as Lung Cancer and Bladder Cancer.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Immune Checkpoint Inhibitors market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Immune Checkpoint Inhibitors market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Immune Checkpoint Inhibitors market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Immune Checkpoint Inhibitors market in these regions.

MARKET PLAYERS
The reports cover key developments in the Immune Checkpoint Inhibitors Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Immune Checkpoint Inhibitors Market are anticipated to lucrative growth opportunities in the future with the rising demand for Immune Checkpoint Inhibitors in the global market. Below mentioned is the list of few companies engaged in the Immune Checkpoint Inhibitors market.

The report also includes the profiles of key Immune Checkpoint Inhibitors market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company (ARMO BioSciences)
  • Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
  • Immutep Limited
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono, Inc.)
  • Novartis AG
  • Pfizer Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Immune Checkpoint Inhibitors Market - By Type
1.3.2 Immune Checkpoint Inhibitors Market - By Application
1.3.3 Immune Checkpoint Inhibitors Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. IMMUNE CHECKPOINT INHIBITORS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. IMMUNE CHECKPOINT INHIBITORS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. IMMUNE CHECKPOINT INHIBITORS MARKET - GLOBAL MARKET ANALYSIS
6.1. IMMUNE CHECKPOINT INHIBITORS - GLOBAL MARKET OVERVIEW
6.2. IMMUNE CHECKPOINT INHIBITORS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. IMMUNE CHECKPOINT INHIBITORS MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. CTLA-4 INHIBITOR
7.3.1. Overview
7.3.2. CTLA-4 Inhibitor Market Forecast and Analysis
7.4. PD-1 INHIBITOR
7.4.1. Overview
7.4.2. PD-1 Inhibitor Market Forecast and Analysis
7.5. PD-L1 INHIBITOR
7.5.1. Overview
7.5.2. PD-L1 Inhibitor Market Forecast and Analysis
8. IMMUNE CHECKPOINT INHIBITORS MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. LUNG CANCER
8.3.1. Overview
8.3.2. Lung Cancer Market Forecast and Analysis
8.4. BLADDER CANCER
8.4.1. Overview
8.4.2. Bladder Cancer Market Forecast and Analysis
8.5. MELANOMA
8.5.1. Overview
8.5.2. Melanoma Market Forecast and Analysis
8.6. HODGKIN LYMPHOMA
8.6.1. Overview
8.6.2. Hodgkin Lymphoma Market Forecast and Analysis
8.7. OTHER APPLICATIONS
8.7.1. Overview
8.7.2. Other Applications Market Forecast and Analysis
9. IMMUNE CHECKPOINT INHIBITORS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Immune Checkpoint Inhibitors Market Overview
9.1.2 North America Immune Checkpoint Inhibitors Market Forecasts and Analysis
9.1.3 North America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
9.1.4 North America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
9.1.5 North America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
9.1.5.1 United States Immune Checkpoint Inhibitors Market
9.1.5.1.1 United States Immune Checkpoint Inhibitors Market by Type
9.1.5.1.2 United States Immune Checkpoint Inhibitors Market by Application
9.1.5.2 Canada Immune Checkpoint Inhibitors Market
9.1.5.2.1 Canada Immune Checkpoint Inhibitors Market by Type
9.1.5.2.2 Canada Immune Checkpoint Inhibitors Market by Application
9.1.5.3 Mexico Immune Checkpoint Inhibitors Market
9.1.5.3.1 Mexico Immune Checkpoint Inhibitors Market by Type
9.1.5.3.2 Mexico Immune Checkpoint Inhibitors Market by Application
9.1.5.4 US Immune Checkpoint Inhibitors Market
9.1.5.4.1 US Immune Checkpoint Inhibitors Market by Type
9.1.5.4.2 US Immune Checkpoint Inhibitors Market by Application
9.2. EUROPE
9.2.1 Europe Immune Checkpoint Inhibitors Market Overview
9.2.2 Europe Immune Checkpoint Inhibitors Market Forecasts and Analysis
9.2.3 Europe Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
9.2.4 Europe Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
9.2.5 Europe Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Immune Checkpoint Inhibitors Market
9.2.5.1.1 Germany Immune Checkpoint Inhibitors Market by Type
9.2.5.1.2 Germany Immune Checkpoint Inhibitors Market by Application
9.2.5.2 France Immune Checkpoint Inhibitors Market
9.2.5.2.1 France Immune Checkpoint Inhibitors Market by Type
9.2.5.2.2 France Immune Checkpoint Inhibitors Market by Application
9.2.5.3 Italy Immune Checkpoint Inhibitors Market
9.2.5.3.1 Italy Immune Checkpoint Inhibitors Market by Type
9.2.5.3.2 Italy Immune Checkpoint Inhibitors Market by Application
9.2.5.4 Spain Immune Checkpoint Inhibitors Market
9.2.5.4.1 Spain Immune Checkpoint Inhibitors Market by Type
9.2.5.4.2 Spain Immune Checkpoint Inhibitors Market by Application
9.2.5.5 United Kingdom Immune Checkpoint Inhibitors Market
9.2.5.5.1 United Kingdom Immune Checkpoint Inhibitors Market by Type
9.2.5.5.2 United Kingdom Immune Checkpoint Inhibitors Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Immune Checkpoint Inhibitors Market Overview
9.3.2 Asia-Pacific Immune Checkpoint Inhibitors Market Forecasts and Analysis
9.3.3 Asia-Pacific Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Immune Checkpoint Inhibitors Market
9.3.5.1.1 Australia Immune Checkpoint Inhibitors Market by Type
9.3.5.1.2 Australia Immune Checkpoint Inhibitors Market by Application
9.3.5.2 China Immune Checkpoint Inhibitors Market
9.3.5.2.1 China Immune Checkpoint Inhibitors Market by Type
9.3.5.2.2 China Immune Checkpoint Inhibitors Market by Application
9.3.5.3 India Immune Checkpoint Inhibitors Market
9.3.5.3.1 India Immune Checkpoint Inhibitors Market by Type
9.3.5.3.2 India Immune Checkpoint Inhibitors Market by Application
9.3.5.4 Japan Immune Checkpoint Inhibitors Market
9.3.5.4.1 Japan Immune Checkpoint Inhibitors Market by Type
9.3.5.4.2 Japan Immune Checkpoint Inhibitors Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Immune Checkpoint Inhibitors Market Overview
9.4.2 Middle East and Africa Immune Checkpoint Inhibitors Market Forecasts and Analysis
9.4.3 Middle East and Africa Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Immune Checkpoint Inhibitors Market
9.4.5.1.1 South Africa Immune Checkpoint Inhibitors Market by Type
9.4.5.1.2 South Africa Immune Checkpoint Inhibitors Market by Application
9.4.5.2 Saudi Arabia Immune Checkpoint Inhibitors Market
9.4.5.2.1 Saudi Arabia Immune Checkpoint Inhibitors Market by Type
9.4.5.2.2 Saudi Arabia Immune Checkpoint Inhibitors Market by Application
9.4.5.3 U.A.E Immune Checkpoint Inhibitors Market
9.4.5.3.1 U.A.E Immune Checkpoint Inhibitors Market by Type
9.4.5.3.2 U.A.E Immune Checkpoint Inhibitors Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Immune Checkpoint Inhibitors Market Overview
9.5.2 South and Central America Immune Checkpoint Inhibitors Market Forecasts and Analysis
9.5.3 South and Central America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
9.5.4 South and Central America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
9.5.5 South and Central America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Immune Checkpoint Inhibitors Market
9.5.5.1.1 Brazil Immune Checkpoint Inhibitors Market by Type
9.5.5.1.2 Brazil Immune Checkpoint Inhibitors Market by Application
9.5.5.2 Argentina Immune Checkpoint Inhibitors Market
9.5.5.2.1 Argentina Immune Checkpoint Inhibitors Market by Type
9.5.5.2.2 Argentina Immune Checkpoint Inhibitors Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. IMMUNE CHECKPOINT INHIBITORS MARKET, KEY COMPANY PROFILES
11.1. ASTRAZENECA
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BRISTOLMYERS SQUIBB COMPANY
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ELI LILLY AND COMPANY
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. FORTRESS BIOTECH
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. F. HOFFMANN LA ROCHE LTD
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. IMMUTEP
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK & CO., INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. MERCK KGAA
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. NOVARTIS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PFIZER INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. AstraZeneca Plc.
2. Bristol-Myers Squibb Company
3. Eli Lilly and Company (ARMO BioSciences)
4. Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
5. F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
6. Immutep Limited
7. Merck & Co., Inc.
8. Merck KGaA (EMD Serono, Inc.)
9. Novartis AG
10. Pfizer Inc.